JP2002535286A5 - - Google Patents

Download PDF

Info

Publication number
JP2002535286A5
JP2002535286A5 JP2000594486A JP2000594486A JP2002535286A5 JP 2002535286 A5 JP2002535286 A5 JP 2002535286A5 JP 2000594486 A JP2000594486 A JP 2000594486A JP 2000594486 A JP2000594486 A JP 2000594486A JP 2002535286 A5 JP2002535286 A5 JP 2002535286A5
Authority
JP
Japan
Prior art keywords
cpn10
ifn
pharmaceutically effective
effective amount
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000594486A
Other languages
English (en)
Japanese (ja)
Other versions
JP4691257B2 (ja
JP2002535286A (ja
Filing date
Publication date
Priority claimed from AUPP8239A external-priority patent/AUPP823999A0/en
Application filed filed Critical
Publication of JP2002535286A publication Critical patent/JP2002535286A/ja
Publication of JP2002535286A5 publication Critical patent/JP2002535286A5/ja
Application granted granted Critical
Publication of JP4691257B2 publication Critical patent/JP4691257B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000594486A 1999-01-20 2000-01-20 シャペロニン１０及びβ−インターフェロンによる多発性硬化症の治療方法 Expired - Fee Related JP4691257B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU8239 1999-01-20
AUPP8239 1999-01-20
AUPP8239A AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment
PCT/AU2000/000032 WO2000043033A1 (en) 1999-01-20 2000-01-20 CHAPERONIN 10 AND β-INTERFERON THERAPY OF MULTIPLE SCLEROSIS

Publications (3)

Publication Number Publication Date
JP2002535286A JP2002535286A (ja) 2002-10-22
JP2002535286A5 true JP2002535286A5 (https=) 2007-02-15
JP4691257B2 JP4691257B2 (ja) 2011-06-01

Family

ID=3812443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000594486A Expired - Fee Related JP4691257B2 (ja) 1999-01-20 2000-01-20 シャペロニン１０及びβ−インターフェロンによる多発性硬化症の治療方法

Country Status (12)

Country Link
US (1) US20090214473A1 (https=)
EP (1) EP1150703B1 (https=)
JP (1) JP4691257B2 (https=)
KR (1) KR100694011B1 (https=)
AT (1) ATE313332T1 (https=)
AU (2) AUPP823999A0 (https=)
CA (1) CA2361081C (https=)
DE (1) DE60024967T2 (https=)
DK (1) DK1150703T3 (https=)
ES (1) ES2255484T3 (https=)
PT (1) PT1150703E (https=)
WO (1) WO2000043033A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548985A (en) * 2004-01-16 2010-02-26 Cbio Ltd Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
EP2457930A1 (en) 2005-08-31 2012-05-30 CBIO Limited Modified chaperonin 10
CN101330922A (zh) * 2005-10-20 2008-12-24 悉生物有限公司 超敏的治疗
CA2644058C (en) * 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015339A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Antagonists to chaperonin 10
JPH10500109A (ja) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療方法
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose

Similar Documents

Publication Publication Date Title
CA2319201A1 (en) Celecoxib compositions
PT871465E (pt) Utilizacao de ritonavir (abt-538) para melhorar a farmacocinetica de drogas metabolizadas por citocromo p450 num metodo de tratamento da sida
WO2004110346A3 (en) Sustained release of antiinfectives
CA2274910A1 (en) Flat medicament preparation for the application and release of buprenorphine or a pharmacologically comparable substance in the buccal cavity, and method of producing the same
JP2002524415A5 (https=)
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
JP2004507496A5 (https=)
JP2002528502A5 (https=)
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
GB0406384D0 (en) Composition for reducing appetite in mammals comprising proxyanidin
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
IL158155A (en) Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
JP2002535286A5 (https=)
CA2365412A1 (en) Orally administrable solid ribavirin dosage forms and process for making them
CA2139385A1 (en) Products containing g-csf and tnf binding protein
CA2030962A1 (en) Improvements relating to the administration of pharmaceutical agents
CA2113916A1 (en) 6-Chloro-5-Fluoro-3-(2-Thenoyl)-2-Oxindole-1-Carboxamide as an Analgesic and Anti-Inflammatory Agent
JP2002523437A5 (https=)
CA2202397A1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
JP2002522501A5 (https=)
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
JP2001513504A5 (https=)
JP2003514025A5 (https=)
JP2004525940A5 (https=)